TORONTO, Sept. 30 /CNW/ - The K2 Principal Fund L.P. ("K2") announced
that it has acquired common shares of CryoCath Technologies Inc. ("CryoCath").
As a result of the acquisition of such shares, K2 owns 2,855,700 common
shares, representing approximately 6.69% of the issued and outstanding common
shares of CryoCath.
The common shares were purchased by K2 in the open market on the Toronto
Stock Exchange. K2 acquired the securities for investment purposes only and
may, depending on market and other conditions, increase or decrease its
beneficial ownership, control or direction over, or exercise its current
rights to acquire, common shares or other securities of CryoCath through
market transactions, private agreements or otherwise.
For further information:
For further information: Daniel Gosselin, The K2 Principal Fund L.P.,